Business context and reporting period
The filing is Galapagos NV’s Form 20-F annual report for the fiscal year ended December 31, 2020, prepared under IFRS in euros. The supplied metadata names Lakefront Biotherapeutics NV, but the filing identifies the registrant as Galapagos NV, a Belgian integrated biopharmaceutical company. Galapagos focuses on discovering, developing and commercializing medicines in inflammation, fibrosis and related therapeutic areas.
In 2020, Galapagos operated primarily as a single research and development segment after classifying its fee-for-service business, Fidelta, as discontinued operations. Fidelta was sold to Selvita for €37.1 million on January 4, 2021.
Key financial metrics
| Metric | 2020 | 2019 | Change |
|---|---|---|---|
| Revenue | €478.1 million | €834.9 million | Down 43% |
| Total revenue and other income | €530.3 million | €885.8 million | Down 40% |
| Research and development expense | €523.7 million | €420.1 million | Up 25% |
| Sales and marketing expense | €66.5 million | €24.6 million | Up 170% |
| General and administrative expense | €118.8 million | €72.4 million | Up 64% |
| Operating income/(loss) | €(178.6) million | €368.7 million | Shifted to loss |
| Net income/(loss) | €(305.4) million | €149.8 million | Shifted to loss |
| Basic loss/(income) per share | €(4.69) | €2.60 | Not comparable directionally |
| Operating cash flow | €(427.3) million | €3.21 billion | Down €3.64 billion |
| Capital expenditures | €91.3 million | €45.7 million | Up approximately 100% |
Revenue consisted principally of collaboration-related upfront and license revenue of €411.4 million, milestone payments of €46.3 million, reimbursement income of €4.1 million and commercial revenue of €16.2 million, including €16.2 million of filgotinib royalties.
At December 31, 2020, cash and cash equivalents were €2.14 billion, current financial investments were €3.03 billion, and combined cash and current investments were €5.17 billion. Total equity was €2.67 billion and total liabilities were €3.05 billion. The company reported no long-term debt other than lease liabilities.
Material changes versus the prior comparable period
- Revenue fell primarily because 2019 included €667.0 million of point-in-time revenue from the Gilead collaboration related to ziritaxestat. In 2020, revenue included €229.6 million recognized over time for access to the drug discovery platform and €228.1 million related to the filgotinib performance obligation.
- Gilead-related revenue also benefited from €90.2 million of regulatory approval milestones for filgotinib in Europe and Japan and €16.2 million of royalties.
- Operating expenses increased substantially as the pipeline matured and the company prepared for commercialization of Jyseleca in Europe. R&D spending increased 25%, sales and marketing spending increased 170%, and general and administrative spending increased 64%.
- The 2020 loss included €152.8 million of other financial expenses, including a €110.4 million currency exchange loss, primarily on U.S.-dollar deposits and investments, and €15.9 million of fair value losses on current financial investments.
- In December 2020, Galapagos and Gilead agreed to transfer European development, manufacturing and commercialization responsibilities for filgotinib to Galapagos. Galapagos expects to assume European commercial economics from January 1, 2022, subject to royalties to Gilead of 8% to 15% of European net sales beginning in 2024.
- The company’s estimated filgotinib cost-sharing commitment declined from €614.1 million at December 31, 2019 to €493.4 million following the renegotiation, although Galapagos assumed additional development responsibilities from January 1, 2021.
- Gilead’s ownership was 25.54% at December 31, 2020. Gilead’s initial Warrant A expired in October 2020; the initial Warrant B remained outstanding.
Guidance, outlook, commentary and risks
Management stated that existing cash, current financial investments and expected operating resources should fund operating expenses and capital expenditures for the coming years and at least 12 months, based on current assumptions. Management also expects continued operating losses, with higher costs as Galapagos builds a European commercial infrastructure and assumes greater responsibility for filgotinib.
Management expects capital expenditures to increase in the near term. Planned investments include new facilities in Leiden, estimated at approximately €79 million, and ongoing investment in Mechelen facilities. Outstanding purchase commitments were €347.9 million at December 31, 2020, excluding the separately disclosed filgotinib cost-sharing commitment.
- Filgotinib was approved for rheumatoid arthritis in Europe and Japan in September 2020 and marketed as Jyseleca. European approval for ulcerative colitis was under review, while Crohn’s disease remained in Phase 3 development.
- Gilead received a Complete Response Letter from the FDA for filgotinib in U.S. rheumatoid arthritis and decided not to advance the U.S. application for that indication. The filing cites ongoing uncertainty regarding the male reproductive safety data and the benefit-risk profile of the 200 mg dose.
- GLPG1205 showed a favorable FVC trend in the Phase 2 PINTA trial in idiopathic pulmonary fibrosis, but the study was not powered to demonstrate statistical significance. GLPG4716 was in preparation for Phase 2 development.
- The ROCCELLA Phase 2b trial for GLPG1972 in osteoarthritis failed to meet its primary endpoint, and development was discontinued. Gilead declined its option on the program in November 2020.
- Subsequent to year-end, in February 2021, Galapagos and Gilead discontinued all development of ziritaxestat after an independent data monitoring committee concluded that its benefit-risk profile no longer supported continuing the ISABELA Phase 3 trials.
- COVID-19 caused or could continue to cause delays in clinical trial enrollment, site initiation, regulatory reviews, manufacturing and supply chains, although management reported limited financial statement impact in 2020 and no material impact on commercial filgotinib supply at the reporting date.
- Key risks include dependence on Gilead, the execution and cost of transitioning European filgotinib operations, uncertain clinical and regulatory outcomes, product safety and reproductive-toxicity concerns, reimbursement and pricing pressure, competition, intellectual property challenges, foreign-exchange volatility and the need for additional capital if spending exceeds expectations.
Facts investors should verify
- Confirm that the intended registrant is Galapagos NV rather than Lakefront Biotherapeutics NV, and that the relevant period is the fiscal year ended December 31, 2020 rather than a standalone fourth quarter.
- Review the Gilead amendment, including the €160 million payment schedule, the transfer of European responsibilities, the 8% to 15% European royalty obligation and the 20% to 30% ex-Europe royalty structure.
- Assess the sustainability and quality of revenue, given that 2020 revenue was overwhelmingly collaboration-related and 99% of revenue was attributed to Gilead in the filing’s customer concentration disclosure.
- Reconcile the €5.17 billion liquidity balance with the €427.3 million operating cash outflow, €91.3 million of capital expenditures, €493.4 million filgotinib cost-sharing commitment and €347.9 million of purchase commitments.
- Evaluate the impact of the U.S. regulatory setback, male reproductive safety studies, European commercialization transition and subsequent discontinuation of ziritaxestat on the pipeline and future revenue profile.
- Review the accounting judgments surrounding IFRS 15 revenue recognition and the €818.7 million deferred income balance associated with the filgotinib performance obligation.
- Consider foreign-exchange exposure: approximately $1.42 billion of cash and current financial investments were held in U.S. dollars at year-end, and 2020 included a €110.4 million currency exchange loss.